<DOC>
	<DOCNO>NCT01047254</DOCNO>
	<brief_summary>Apathy dementia prevents successful application non-pharmacological treatment , accelerate cognitive functional decline increase disease-related cost earlier need full-time care . Apathy distinct entity occur independently neuropsychiatric syndrome , like depression . Today , high-level evidence effective treatment apathy AD . In contrast neuropsychiatric syndrome AD , like psychosis depression , despite high prevalence clinical relevance , apathy never primary outcome clinical trial . Basic clinical research provide distinct model pathophysiology apathy dopamine norepinephrine key neurotransmitter system involve . The antidepressant Bupropion dopamine norepinephrine reuptake inhibitor . There evidence case-series , Bupropion reduce apathy patient organic brain disorder . This study test efficacy safety Bupropion treatment apathy AD 12-week multicenter doubleblind placebo control trial . Secondary endpoint quality life patient , caregiver ' distress , ability patient perform activity daily live , utilization healthcare resource patient caregiver , cognitive function .</brief_summary>
	<brief_title>Bupropion Treatment Apathy Alzheimer 's Dementia</brief_title>
	<detailed_description />
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Mild moderate Alzheimer 's dementia , male female ( NINCDS/ADRDA criterion ) Presence clinically relevant apathy define Neuropsychiatric Inventory ( NPI ) apathy item ( score &gt; /= 4 point ) Marin/Starkstein criterion apathy MMSE : 1025 Outpatient status , institutionalize Presence reliable caregiver Stable treatment antidementia drug least three month prior entry treatment antidementia drug Other Dementia ( e.g . vascular dementia , Lewybody dementia , frontotemporal dementia ) Presence clinically relevant depression define either NPI depression item ( score &gt; /= 4 point ) DSMIV criterion major depressive episode ( depressed mood ) Alcoholism Benzodiazepine addiction Current treatment antipsychotic antidepressant ( include St. John 's wart ) Current treatment dopaminergic agent Amantadin Current treatment benzodiazepine Current treatment MAO inhibitor ( Bupropion contraindication ) Known sensibility Bupropion treatment Severe psychiatric disease ( include hospitalization ) last 6 month , suicide attempt , acute psychotic symptom Severe physical illness , allow participation 12week period treatment Medical history seizures Medical history tumor central nervous system Severe craniocerebral injury medical history cerebral substance defect Clinically relevant renal disease , liver insufficiency Simultaneous treatment , reduce seizure threshold ( e.g . antipsychotic , antidepressant , antimalarial agent , Tramadol , Theophyllin , systemic steroid higher dose , Chinolone , sedative antihistamine ) Simultaneous treatment , metabolize Cytochrom P450Isoenzym 2D6 ( e.g . beta blocker : Metoprolol , Proanolol , Timolol , Carvediol , Nebivolol , Typ1CAntiarrhyhtmics e.g . Propafenon , Flecinid ) ( except Donepezil Galantamin ) Simultaneous treatment drug , may interfere metabolization Bupropion ( e.g . Carbamazepin , Phenytoin , Valproat , Ritonavir , Lopinavir ) Diabetes mellitus , therapeutically poorly regulate treated medication Treatment stimulants appetite depressant Participation clinical trial last 3 month Suicidal tendency Known lactose intolerance</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>